Cross-Switch from Etanercept Originator to Biosimilar SB4 and to GP2015 in Patients with Chronic Plaque Psoriasis

Dear Editor, Biosimilars of anti-TNF-a inhibitors have become a valid and usually less expensive alternative to their originator drugs [1]. [...]switching from originator to biosimilar drugs is an increasingly widespread approach because of the potential cost savings. [...]etanercept, both originator and biosimilar, has shown to be associated with a low risk of immunogenicity and the very infrequent ADA to etanercept are non-neutralizing [5]. [...]the EGALITY study on psoriatic patients showed that there are no effects on the production of ADA with multiple switches between GP2015 and Enbrel [6]. [...]biosimilars represent an important opportunity for earlier and equal access to biological treatment, reducing the growing pressure on health care budgets and being a viable treatment option for a larger number of patients.